Identification of SARS-CoV-2 variants using viral sequencing for the Centers for Disease Control and Prevention genomic surveillance program

The Centers for Disease Control and Prevention contracted with laboratories to sequence the SARS-CoV-2 genome from positive samples across the United States to enable public health officials to investigate the impact of variants on disease severity as well as the effectiveness of vaccines and treatm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC infectious diseases 2022-04, Vol.22 (1), p.404-404, Article 404
Hauptverfasser:	Goswami, Chirayu, Sheldon, Michael, Bixby, Christian, Keddache, Mehdi, Bogdanowicz, Alexander, Wang, Yihe, Schultz, Jonathan, McDevitt, Jessica, LaPorta, James, Kwon, Elaine, Buyske, Steven, Garbolino, Dana, Biloholowski, Glenys, Pastuszak, Alex, Storella, Mary, Bhalla, Amit, Charlier-Rodriguez, Florence, Hager, Russ, Grimwood, Robin, Nahas, Shareef A
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Centers for Disease Control Centers for Disease Control and Prevention, U.S Coronaviruses COVID-19 COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines Cycle threshold Disease control Disease transmission DNA sequencing Ethnicity FDA approval Gene sequencing Genes Genomes Genomics Humans Laboratories Manufacturers Medical care N gene Next generation sequencing Nucleic acids Nucleotide sequence Nucleotide sequencing Patients Polymerase chain reaction Prevention Public health Quality control Quality management Reverse transcription polymerase chain reaction Saliva SARS-CoV-2 SARS-CoV-2 - genetics Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Surveillance Testing United States - epidemiology Vaccines Viral diseases Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The Centers for Disease Control and Prevention contracted with laboratories to sequence the SARS-CoV-2 genome from positive samples across the United States to enable public health officials to investigate the impact of variants on disease severity as well as the effectiveness of vaccines and treatment. Herein we present the initial results correlating RT-PCR quality control metrics with sample collection and sequencing methods from full SARS-CoV-2 viral genomic sequencing of 24,441 positive patient samples between April and June 2021. RT-PCR confirmed (N Gene Ct value
ISSN:	1471-2334 1471-2334
DOI:	10.1186/s12879-022-07374-7